A recent multi-omic analysis, spanning over several cancer types, suggests that CDK17 is generally up-regulated in malignant tumors, associated with activation of epithelial-mesenchymal transition (EMT) and estrogen receptor pathways and with inhibition of apoptosis, cell cycle, and DNA damage response [110]. Here, ESR1 is linked to cancer.